title: Maintenance Oral Nifedipine for Management of Symptomatic Placenta Previa : A Randomized Clinical Trial

summary:
The objective of our study is to determine the clinical utility related to the maintenance oral nifedipine therapy in patients with symptomatic placenta previa. This study is a prospective, randomized controlled trial with the inclusion, after 24 weeks gestation, of hospitalized patients with symptomatic placenta praevia. All patients may initially receive oral nifedipine therapy with steroid prophylaxis for 48 hours. After then, patients are randomly assigned to receive either oral nifedipine (20 mg every 8 hours) or placebo (one every 8 hours) until 37 weeks of gestation.

The primary outcome for the trial is the length of pregnancy in days after the enrollment. A sample size calculation is designed to detect at least a 14 -day difference in time gained in patients with maintenance oral nifedipine therapy. A sample size of about 52 patients per group would have a 80 % chance of detecting this difference at the 5 % level of significance.

ReferenceCitation: Verspyck E, de Vienne C, Muszynski C, Bubenheim M, Chanavaz-Lacheray I, Dreyfus M, Deruelle P, Benichou J. Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial. PLoS One. 2017 Mar 23;12(3):e0173717. doi: 10.1371/journal.pone.0173717. eCollection 2017.

family: Verspyck

full_name: Eric Verspyck

given: Eric

family: de Vienne

full_name: Claire de Vienne

family: Muszynski

full_name: Charles Muszynski

given: Charles

family: Bubenheim

full_name: Michael Bubenheim

given: Michael

family: Chanavaz-Lacheray

full_name: Isabella Chanavaz-Lacheray

given: Isabella

family: Dreyfus

full_name: Michel Dreyfus

given: Michel

family: Deruelle

full_name: Philippe Deruelle

given: Philippe

family: Benichou

full_name: Jacques Benichou

given: Jacques

currency_apc_doaj: USD

journal_name: PLOS ONE

evidence: oa repository (semantic scholar lookup)

version: submittedVersion

publisher: Public Library of Science (PLoS)

publisher_dissemination: Public Library of Science

publisher_group: Public Library of Science

publisher_normalized: Public Library of Science


title: A Multicenter, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Consisting of Either a Docetaxel - Letrozole Combination or Letrozole Alone in Women Over 60 Years of Age Suffering From Grade I or II Operable Hormone Receptor-positive Breast Tumor.

summary: Primarily to evaluate the rates of clinical and radiological response in the 2 groups. Secondarily rate of histological response.

status: Completed

study_completion_date_type: Actual

study_type: Interventional

design_allocation: Randomized

primary_purpose: Treatment

enrollment_type: Actual

lead_sponsor: Sanofi

intervention_type: Drug

lead_sponsor_type: industriel

status_simplified: Completed


title: Role of Nocturnal Respiratory Disorders on Ischemic Stroke Occurrence

acronym: AVSAS

summary:
Stroke is the third leading cause of death in industrialized countries and the first cause of handicap in adults. Several stroke risk factors were identified such as high blood pressure, diabetes mellitus, hypercholesterolemia or cardiac arrhythmias. Sleep respiratory disorders have been found to be frequent among patients with stroke. Among them obstructive sleep apnea (OSA) syndrome seems to be the most important due to its association with high blood pressure and atrial fibrillation.

Stroke can be responsible of central apneas, therefore the differential diagnosis between central apneas and pure OSA after stroke is sometimes difficult. The misidentification of OSA can explain the poor tolerance of CPAP treatment by these patients. The purpose of the present study is to investigate the association between pre-stroke OSA syndrome OSA diagnosed on specific scales and confirmed by polygraphic studies and stroke occurrence.

study_type: Observational

time_perspective: Prospective

lead_sponsor: University Hospital, Bordeaux

location_facility: Groupe Hospitalier Pellegrin - Place Amélie Raba Léon

intervention_type: Other

lead_sponsor_type: academique


title: Assessment of the Use of Fixed Doses of Artesunate Plus Amodiaquine Combination for the Home Management of Presumed Malaria in Malagasy Children

summary: The purpose of this study is to assess the feasibility, the acceptability and the effectiveness of the use of the Artesunate + Amodiaquine Fixed Dose Combination for the home management of presumed malaria in Malagasy children by the community-based service providers.

ReferenceType: derived

ReferenceCitation: Ratsimbasoa A, Ravony H, Vonimpaisomihanta JA, Raherinjafy R, Jahevitra M, Rapelanoro R, Rakotomanga Jde D, Malvy D, Millet P, Ménard D. Management of uncomplicated malaria in febrile under five-year-old children by community health workers in Madagascar: reliability of malaria rapid diagnostic tests. Malar J. 2012 Mar 25;11:85. doi: 10.1186/1475-2875-11-85.

family: Ratsimbasoa

full_name: Arsène Ratsimbasoa

given: Arsène

sequence: first

family: Ravony

full_name: Harintsoa Ravony

given: Harintsoa

sequence: additional

family: Vonimpaisomihanta

full_name: Jeanne-Aimée Vonimpaisomihanta

given: Jeanne-Aimée

family: Raherinjafy

full_name: Rogelin Raherinjafy

given: Rogelin

family: Jahevitra

full_name: Martial Jahevitra

given: Martial

family: Rapelanoro

full_name: Rabenja Rapelanoro

given: Rabenja

family: Rakotomanga

full_name: Jean De Dieu Marie Rakotomanga

given: Jean De Dieu Marie

family: Malvy

full_name: Denis Malvy

given: Denis

family: Millet

full_name: Pascal Millet

given: Pascal

family: Ménard

full_name: Didier Ménard

given: Didier

bso_classification: Medical research

currency_apc_doaj: GBP

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: Malaria Journal

oa_colors: green gold

oa_host_type: publisher;repository

evidence: oa journal (via doaj)

host_type: publisher

license: cc-by

license_normalized: cc-by

version: publishedVersion

evidence: oa repository (via OAI-PMH doi match)

host_type: repository

repository_institution: PubMed Central - Europe PMC

repository_normalized: PubMed Central

evidence: oa repository (via pmcid lookup)

license_normalized: no license

publisher: Springer Science and Business Media LLC

publisher_dissemination: Springer

publisher_group: Springer

publisher_normalized: Springer

lead_sponsor: National Malaria Control Programme, Madagascar


title: Parallel Randomised Open Phase II Study of Oxaliplatin (L-OHP) Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Locally Advanced or Metastatic Endometrial Cancer Previously Treated With Cisplatin or Arboplatin

summary: To determine the efficacy (response rate [RR], time to progression and survival) of oxaliplatin as a single agent and oxaliplatin in combination with 5 FU in patients with advanced/metastatic endometrial cancer pretreated with one prior chemotherapy regimen containing cisplatin (CDDP) or carboplatin and to define the safety profile of each arm of the above mentioned regimens in these patients


title: Phase II Study of Combined Oxaliplatin and Paclitaxel for Metastatic Germ Cell Tumors

summary: To evaluate the efficacy of the oxaliplatin-paclitaxel combination i.e. evaluation of tumor response rate using World Health Organization/Union Internationale Contre le Cancer (WHO/UICC) and Indianapolis tumor marker (human chorionic gonadotropin [hCG], alpha fetoprotein [AFP]) criteria in metastatic germ cell cancer patients

design_allocation: Non-Randomized


title: Phase II Study of Oxaliplatin in Combination With 5-Fluorouracil (5-FU) in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck

summary: To evaluate the efficacy of first line oxaliplatin in combination with 5-fluorouracil (5-FU) in patients with advanced inoperable or metastatic head and neck cancer and to investigate the safety profile of this regimen in the above indication and consider other criteria of efficacy (clinical benefit, survival)


title: VACCILUP "A Multicenter, Randomized Double-blind Trial Comparing Two Pneumococcal Vaccination Strategies in Patients With Systemic Lupus Erythematosus"

acronym: VACCILUP

summary: The aim of this study is to compare the immunological efficacy of two pneumococcal vaccination strategies in patients with systemic lupus erythematosus (SLE) treated with corticosteroids associated or not with other immunosuppressive drugs : 1) a prime-boost strategy using vaccination with conjugate vaccine (Prevenar®) at week 0 and Poly Saccharidic vaccine (Pneumo23®) after 6 months (W24)2) compared to the standard vaccination with Poly Saccharidic vaccine (Pneumo23®) at W24 after placebo at W0

ReferenceCitation: Grabar S, Groh M, Bahuaud M, Le Guern V, Costedoat-Chalumeau N, Mathian A, Hanslik T, Guillevin L, Batteux F, Launay O; VACCILUP study group. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study. Vaccine. 2017 Sep 5;35(37):4877-4885. doi: 10.1016/j.vaccine.2017.07.094. Epub 2017 Aug 4.

family: Grabar

full_name: Sophie Grabar

given: Sophie

family: Groh

full_name: Matthieu Groh

given: Matthieu

family: Bahuaud

full_name: Mathilde Bahuaud

given: Mathilde

family: Le Guern

full_name: Véronique Le Guern

given: Véronique

family: Costedoat-Chalumeau

full_name: Nathalie Costedoat-Chalumeau

given: Nathalie

family: Mathian

full_name: Alexis Mathian

given: Alexis

family: Hanslik

full_name: Thomas Hanslik

given: Thomas

family: Guillevin

full_name: Loïc Guillevin

given: Loïc

family: Batteux

full_name: Frédéric Batteux

given: Frédéric

family: Launay

full_name: Odile Launay

given: Odile

journal_name: Vaccine

publisher: Elsevier BV

publisher_dissemination: Elsevier

publisher_group: Elsevier

publisher_normalized: Elsevier

lead_sponsor: Assistance Publique - Hôpitaux de Paris

intervention_type: Biological


title: Sulfonylureas in Neonatal Diabetes Mellitus With Mutations of 2 Type of Subunits Kir6.2 and SUR1 of the Pancreatic Beta-cell ATP-sensitive K+ Channel.

summary: The aim of our trial is to try to switch patients with permanent neonatal diabetes mellitus due to a Kir6.2 or SUR1 activating mutation from subcutaneous insulin to oral glibenclamide therapy.

ReferenceCitation: Beltrand J, Elie C, Busiah K, Fournier E, Boddaert N, Bahi-Buisson N, Vera M, Bui-Quoc E, Ingster-Moati I, Berdugo M, Simon A, Gozalo C, Djerada Z, Flechtner I, Treluyer JM, Scharfmann R, Cavé H, Vaivre-Douret L, Polak M; GlidKir Study Group. Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel Mutations. Diabetes Care. 2015 Nov;38(11):2033-41. doi: 10.2337/dc15-0837. Epub 2015 Oct 5. Erratum in: Diabetes Care. 2016 Jan;39(1):175.

family: Beltrand

full_name: Jacques Beltrand

given: Jacques

family: Elie

full_name: Caroline Elie

given: Caroline

family: Busiah

full_name: Kanetee Busiah

given: Kanetee

family: Fournier

full_name: Emmanuel Fournier

given: Emmanuel

family: Boddaert

full_name: Nathalie Boddaert

family: Bahi-Buisson

full_name: Nadia Bahi-Buisson

given: Nadia

family: Vera

full_name: Miriam Vera

given: Miriam

family: Bui-Quoc

full_name: Emmanuel Bui-Quoc

family: Ingster-Moati

full_name: Isabelle Ingster-Moati

given: Isabelle

family: Berdugo

full_name: Marianne Berdugo

given: Marianne

family: Simon

full_name: Albane Simon

given: Albane

family: Gozalo

full_name: Claire Gozalo

given: Claire

family: Djerada

full_name: Zoubir Djerada

given: Zoubir

family: Flechtner

full_name: Isabelle Flechtner

family: Treluyer

full_name: Jean-Marc Treluyer

given: Jean-Marc

family: Scharfmann

full_name: Raphael Scharfmann

given: Raphael

family: Cavé

full_name: Helene Cavé

given: Helene

family: Vaivre-Douret

full_name: Laurence Vaivre-Douret

given: Laurence

family: Polak

full_name: Michel Polak

given: Michel

journal_name: Diabetes Care

oa_host_type: publisher

evidence: open (via free pdf)

publisher: American Diabetes Association

publisher_dissemination: American Diabetes Association

publisher_group: American Diabetes Association

publisher_normalized: American Diabetes Association

location_facility: Necker Hospital - Endocrinology Gynecology Pediatric unit


title: Synthesis of Glutathione in Erythrocytes From Low Birth Weight Newborn Babies : Effect of Cysteine in Vitro

acronym: glutathione

summary: The aim of the study is to determine mechanisms leading to glutathione deficiency in low birth weight newborn babies. Compared to full term neonates, depletion in this population may be due to a decreased synthesis rate or to an enhanced utilization or a combination of both mechanisms.The protocol is constituted of two steps. The objective of the first step is to quantify the blood concentration of glutathione in the artery and the vein of umbilical cord in full term newborn babies. Objectives of the second step are to determine if the glutathione synthesis rate, measured in vitro, is lower in erythrocytes collected from umbilical cord blood of low weight newborn babies compared to full term newborn babies. In this case, the next objective will be to determine if the adjunction of an excess of cysteine in vitro can restore the glutathione synthesis rate in these cells.

status: Terminated

primary_purpose: Health Services Research

ReferenceCitation: De Luca A, Küster A, Tea I, Darmaun D, Rozé JC, Robins R, Hankard R. Plasma amino acid pools in the umbilical cord artery show lower (15)N natural isotope abundance relative to the maternal venous pools. Isotopes Environ Health Stud. 2021 Mar;57(1):3-10. doi: 10.1080/10256016.2020.1817914. Epub 2020 Sep 24.

name: Inserm UMR 1069, Nutrition, Croissance et Cancer, Tours, France

name: Nutrition Unit, Regional University Hospital Centre, Tours, France

family: De Luca

full_name: Arnaud De Luca

given: Arnaud

name: Neonatal and Pediatric Intensive Care Units, University Hospital Centre, Nantes, France

name: INRAE UMR PhAN, University of Nantes, CRNH-Ouest, Nantes, France

family: Küster

full_name: Alice Küster

given: Alice

name: University of Nantes, CNRS, CEISAM UMR 6230, Nantes, France

family: Tea

full_name: Illa Tea

given: Illa

family: Darmaun

full_name: Dominique Darmaun

given: Dominique

family: Rozé

full_name: Jean-Christophe Rozé

given: Jean-Christophe

family: Robins

full_name: Richard Robins

given: Richard

family: Hankard

full_name: Régis Hankard

given: Régis

bso_classification: Biology (fond.)

journal_name: Isotopes in Environmental and Health Studies

publisher: Informa UK Limited

publisher_dissemination: Informa

publisher_group: Informa

publisher_normalized: Informa

title: Plasma amino acid pools in the umbilical cord artery show lower 15N natural isotope abundance relative to the maternal venous pools

lead_sponsor: Nantes University Hospital

intervention_type: Procedure

status_simplified: Unknown


title: Interest in Biventricular Epicardial Pacing Post Cardiac Surgery in Patients With Left Ventricular Ejection Fractions Less Than 45%

summary: Patients with reduced left ventricular function are at an increased perioperative risk and often need prolonged postoperative treatment on intensive care units. A significant portion of these patients require postoperative pacing. Right ventricular pacing has been shown to be hemodynamically deleterious The aim of this study is to determine which biventricular pacing after cardiac surgery, in patients with reduced left ventricular function (EF≤ 45%), is hemodynamically favourable.

status: Unknown status

study_completion_date_type: Anticipated

enrollment_type: Anticipated

ReferenceCitation: Forestier C, Guelon D, Cluytens V, Gillart T, Sirot J, De Champs C. Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients. Crit Care. 2008;12(3):R69. doi: 10.1186/cc6907. Epub 2008 May 20.

family: Forestier

full_name: Christiane Forestier

given: Christiane

family: Guelon

full_name: Dominique Guelon

family: Cluytens

full_name: Valérie Cluytens

given: Valérie

family: Gillart

full_name: Thierry Gillart

given: Thierry

family: Sirot

full_name: Jacques Sirot

given: Jacques

family: De Champs

full_name: Christophe De Champs

given: Christophe

journal_name: Critical Care

lead_sponsor: University Hospital, Clermont-Ferrand


title: Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid

acronym: INWARA

summary:
Several case reports indicate that the use of the antibiotic combination amoxicillin and clavulanic acid (AM-CLAVAC) can interact with warfarin pharmacodynamics. However, fever per se might also be responsible of these warfarin overdose reports, as well as the use of high dose paracetamol.

The aim of the present study is to determine if AM-CLAVAC can increase the pharmacodynamics of warfarin among patients at steady state Double blinded cross over controlled study vs placebo performed in 12 evaluable patients treated with warfarin with an INR target 2 to 3 and a stable INR and a stable dose.

location_facility: Hopital Lariboisière - Service de médecine interne


title: Interest of Using Nocturnal Polysomnography for Non-Invasive Ventilation (NIV) Settings' Optimization in Obesity-Hypoventilation Syndrome (OHS)

acronym: NIV-OHS

summary: The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.

ReferenceCitation: Borel JC, Tamisier R, Gonzalez-Bermejo J, Baguet JP, Monneret D, Arnol N, Roux-Lombard P, Wuyam B, Levy P, Pépin JL. Noninvasive ventilation in mild obesity hypoventilation syndrome: a randomized controlled trial. Chest. 2012 Mar;141(3):692-702. doi: 10.1378/chest.10-2531. Epub 2011 Sep 1.

family: Borel

full_name: Jean-Christian Borel

given: Jean-Christian

family: Tamisier

full_name: Renaud Tamisier

given: Renaud

family: Gonzalez-Bermejo

full_name: Jesus Gonzalez-Bermejo

given: Jesus

family: Baguet

full_name: Jean-Philippe Baguet

given: Jean-Philippe

family: Monneret

full_name: Denis Monneret

given: Denis

family: Arnol

full_name: Nathalie Arnol

given: Nathalie

family: Roux-Lombard

full_name: Pascale Roux-Lombard

given: Pascale

family: Wuyam

full_name: Bernard Wuyam

given: Bernard

family: Levy

full_name: Patrick Levy

given: Patrick

family: Pépin

full_name: Jean-Louis Pépin

given: Jean-Louis

journal_name: Chest

title: Noninvasive Ventilation in Mild Obesity Hypoventilation Syndrome

ReferenceCitation: Borel JC, Roux-Lombard P, Tamisier R, Arnaud C, Monneret D, Arnol N, Baguet JP, Levy P, Pepin JL. Endothelial dysfunction and specific inflammation in obesity hypoventilation syndrome. PLoS One. 2009 Aug 24;4(8):e6733. doi: 10.1371/journal.pone.0006733.

family: Arnaud

full_name: Claire Arnaud

given: Claire

family: Pepin

full_name: Jean-Louis Pepin

journal_name: PLoS ONE

repository_institution: University of Geneva - Archive ouverte UNIGE

title: Endothelial Dysfunction and Specific Inflammation in Obesity Hypoventilation Syndrome

location_facility: Laboratoire d'Explorations Fonctionnelles Cardio-Respiratoires - CHU Grenoble


title: A Multicenter, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance and Safety/Tolerability of SSR180711C for 4 Weeks, Using Donepezil as Calibrator, in Patients With Mild Alzheimer's Disease

summary: The primary objective of the study is to assess the effect of 3 doses of SSR180711C on cognitive performance in patients with mild Alzheimer's Disease (AD). Other objectives are to assess the safety/tolerability of SSR180711C in patients with mild AD.


title: A Multicentric Phase II-III Randomized Study Safety of Intraveinous Liposomal Pegylated Doxorubicin Versus Continuous Infusion of Doxorubicin During Induction Treatment of Acute Lymphoblastic Leukemia in Patients

summary: Phase II multicentric study comparing VAD regimen with continuous infusion over 96 hours of doxorubicin, vincristine and dexamethasone to a 90 minutes infusion of equivalent doses of Dox li-PEG, bolus infusion of vincristine and dexamethasone

ReferenceCitation: Hunault-Berger M, Leguay T, Thomas X, Legrand O, Huguet F, Bonmati C, Escoffre-Barbe M, Legros L, Turlure P, Chevallier P, Larosa F, Garban F, Reman O, Rousselot P, Dhédin N, Delannoy A, Lafage-Pochitaloff M, Béné MC, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica. 2011 Feb;96(2):245-52. doi: 10.3324/haematol.2010.027862. Epub 2010 Oct 22.

family: Hunault-Berger

full_name: M. Hunault-Berger

given: M.

family: Leguay

full_name: T. Leguay

given: T.

family: Thomas

full_name: X. Thomas

given: X.

family: Legrand

full_name: O. Legrand

given: O.

family: Huguet

full_name: F. Huguet

given: F.

family: Bonmati

full_name: C. Bonmati

given: C.

family: Escoffre-Barbe

full_name: M. Escoffre-Barbe

family: Legros

full_name: L. Legros

given: L.

family: Turlure

full_name: P. Turlure

given: P.

family: Chevallier

full_name: P. Chevallier

family: Larosa

full_name: F. Larosa

family: Garban

full_name: F. Garban

family: Reman

full_name: O. Reman

family: Rousselot

full_name: P. Rousselot

family: Dhedin

full_name: N. Dhedin

given: N.

family: Delannoy

full_name: A. Delannoy

given: A.

family: Lafage-Pochitaloff

full_name: M. Lafage-Pochitaloff

family: Bene

full_name: M. C. Bene

given: M. C.

family: Ifrah

full_name: N. Ifrah

family: Dombret

full_name: H. Dombret

given: H.

name: for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)

currency_apc_doaj: EUR

journal_name: Haematologica

license: publisher-specific license

license_normalized: publisher-specific

publisher: Ferrata Storti Foundation (Haematologica)


title: Randomized Double Blind Placebo-controlled Trial of the Efficacy of an Anti-TNF Alpha Agent (Adalimumab, Humira®) in Patients With Incapacitating Hand Osteoarthritis Refractory to Usual Treatment

acronym: DORA

summary:
Digital osteoarthritis (DO) which affects the interphalangeal joints and the Metacarpophalangeal (MCP) of the thumb is a common disease, the prevalence of which increases with age (36% of the population aged over 70). Certain forms of DO with clinical manifestations involving inflammatory features are particularly refractory to usual treatments (analgesics, NSAIDs, braces and local injections). The mechanism of osteoarthritis involves two major cytokines: interleukin-1 beta and tumor necrosis factor alpha. TNF alpha is particularly involved in the inflammation process.

The aim of the present study is to study the efficacy of TNF alpha blockers (2 injections of adalimumab compared to placebo injections in patients with severe and refractory hand osteoarthritis.

We hope that such new therapeutic option may induce substantial pain relief.

ReferenceCitation: Chevalier X, Ravaud P, Maheu E, Baron G, Rialland A, Vergnaud P, Roux C, Maugars Y, Mulleman D, Lukas C, Wendling D, Lafforgue P, Loeuille D, Foltz V, Richette P; French section of osteoarthritis. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis. 2015 Sep;74(9):1697-705. doi: 10.1136/annrheumdis-2014-205348. Epub 2014 May 9.

family: Chevalier

full_name: X Chevalier

given: X

family: Ravaud

full_name: P Ravaud

given: P

family: Maheu

full_name: E Maheu

given: E

family: Baron

full_name: G Baron

given: G

family: Rialland

full_name: A Rialland

given: A

family: Vergnaud

full_name: P Vergnaud

family: Roux

full_name: C Roux

given: C

family: Maugars

full_name: Y Maugars

given: Y

family: Mulleman

full_name: D Mulleman

given: D

family: Lukas

full_name: C Lukas

family: Wendling

full_name: D Wendling

family: Lafforgue

full_name: P Lafforgue

family: Loeuille

full_name: D Loeuille

family: Foltz

full_name: V Foltz

given: V

family: Richette

full_name: P Richette

journal_name: Annals of the Rheumatic Diseases

publisher: BMJ

publisher_dissemination: British Medical Journal

publisher_group: British Medical Journal

publisher_normalized: British Medical Journal


title: A Double Blind, Sequential, Ascending Single Dose, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Study of TC-2216 in Healthy Young Male Volunteers.

acronym: SRD

summary: Targacept, Inc. is studying TC-2216 for a potential role in the treatment of central nervous system (CNS) neurobiological disorders in anticipation of seeking an indication in depression and/or anxiety.

lead_sponsor: Targacept Inc.


title: Erythropoietin Treatment of Anemia Complicating Chronic Obstructive Pulmonary Disease: Functional Impact During Exertion

acronym: ELAB

summary: The purpose of this study is to determine the impact of erythropoietin treatment of anemia on exercise capacity of patients with chronic obstructive pulmonary disease (COPD).

status: Withdrawn


title: Phase II Trial of FOLFOX in Combination With Cetuximab and Concomitant Radiotherapy in the Treatment of Esophageal Cancer Stage III

acronym: FOLFOX

summary: This phase II trial is studying the effects of oxaliplatin, leucovorin and fluorouracil-when given together with Cetuximab and radiation therapy and radiation therapy to see how they work in treating patients with stage III esophageal cancer.


title: Multimodal Magnetic Resonance (MRI) Development in Comatose Patients for an Algorithm in the Prediction of Consciousness Recovery

acronym: MRI-Coma

summary: Stroke, traumatic head injury, subarachnoid hemorrhage and cerebral anoxia are main causes of a coma condition implying severe brain damage and thus, poor prognosis. Clinicians are often in need for a tool able to predict the awakening of these patients. Multimodal MRI, associating the traditional morphological sequences with spectroscopy-MRI (MRS) and the diffusion tensor imaging, could provide such a prediction.

ReferenceCitation: Simeone P, Auzias G, Lefevre J, Takerkart S, Coulon O, Lesimple B, Torkomian G, Battisti V, Jacquens A, Couret D, Naccache L, Bayen E, Bruder N, Perlbarg V, Puybasset L, Velly L. Long-term follow-up of neurodegenerative phenomenon in severe traumatic brain injury using MRI. Ann Phys Rehabil Med. 2021 Oct 27:101599. doi: 10.1016/j.rehab.2021.101599. [Epub ahead of print]

ReferenceCitation: Velly L, Perlbarg V, Boulier T, Adam N, Delphine S, Luyt CE, Battisti V, Torkomian G, Arbelot C, Chabanne R, Jean B, Di Perri C, Laureys S, Citerio G, Vargiolu A, Rohaut B, Bruder N, Girard N, Silva S, Cottenceau V, Tourdias T, Coulon O, Riou B, Naccache L, Gupta R, Benali H, Galanaud D, Puybasset L; MRI-COMA Investigators. Use of brain diffusion tensor imaging for the prediction of long-term neurological outcomes in patients after cardiac arrest: a multicentre, international, prospective, observational, cohort study. Lancet Neurol. 2018 Apr;17(4):317-326. doi: 10.1016/S1474-4422(18)30027-9. Epub 2018 Feb 27.

family: Velly

full_name: Lionel Velly

given: Lionel

family: Perlbarg

full_name: Vincent Perlbarg

given: Vincent

family: Boulier

full_name: Thomas Boulier

given: Thomas

family: Adam

full_name: Nicolas Adam

given: Nicolas

family: Delphine

full_name: Sebastien Delphine

given: Sebastien

family: Luyt

full_name: Charles-Edouard Luyt

given: Charles-Edouard

family: Battisti

full_name: Valentine Battisti

given: Valentine

family: Torkomian

full_name: Gregory Torkomian

given: Gregory

family: Arbelot

full_name: Charlotte Arbelot

given: Charlotte

family: Chabanne

full_name: Russell Chabanne

given: Russell

family: Jean

full_name: Betty Jean

given: Betty

family: Di Perri

full_name: Carol Di Perri

given: Carol

family: Laureys

full_name: Steven Laureys

given: Steven

family: Citerio

full_name: Giuseppe Citerio

given: Giuseppe

family: Vargiolu

full_name: Alessia Vargiolu

given: Alessia

family: Rohaut

full_name: Benjamin Rohaut

given: Benjamin

family: Bruder

full_name: Nicolas Bruder

family: Girard

full_name: Nadine Girard

given: Nadine

family: Silva

full_name: Stein Silva

given: Stein

family: Cottenceau

full_name: Vincent Cottenceau

family: Tourdias

full_name: Thomas Tourdias

family: Coulon

full_name: Olivier Coulon

given: Olivier

family: Riou

full_name: Bruno Riou

given: Bruno

ReferenceCitation: Luyt CE, Galanaud D, Perlbarg V, Vanhaudenhuyse A, Stevens RD, Gupta R, Besancenot H, Krainik A, Audibert G, Combes A, Chastre J, Benali H, Laureys S, Puybasset L; Neuro Imaging for Coma Emergence and Recovery Consortium. Diffusion tensor imaging to predict long-term outcome after cardiac arrest: a bicentric pilot study. Anesthesiology. 2012 Dec;117(6):1311-21. doi: 10.1097/ALN.0b013e318275148c.

name: *Assistant Professor, §§Professor, Service de Réanimation, †Assistant Professor, Service de Neuroradiologie, **Resident, School of Medicine, ##Professor, Service d’Anesthésie-Réanimation, Groupe Hospitalier Pitié–Salpêtrière, Assistance Publique–Hôpitaux de Paris, Université Paris – Pierre-et-Marie-Curie, Paris, France. ‡Enginer, ║Associate Professor, Division of Neuroscience Critical Care, Johns

name: for the Neuro Imaging for Coma Emergence and Recovery Consortium

publisher: Ovid Technologies (Wolters Kluwer Health)

title: Diffusion Tensor Imaging to Predict Long-term Outcome after Cardiac Arrest

location_facility: Assistance Publique Hopitaux de Paris Pitie Salpetriere


title: Pathophysiological Study of Obesity-related Asthma

acronym: BOA

summary: Asthma is more frequent in obese women, but the mechanisms underlying the causes of this increased frequency are unknown and are different from usual asthma pathophysiology (associated with allergy). Obesity is known to influence ventilation; our hypothesis is that the normal variability of ventilation is decreased in obese patients, and that this decrease is responsible for an increased reactivity of their airway to non specific stimuli. In this observational study, breathing variability will be studied using polygraphy (an investigation that is made in these women to detect nocturnal apneas), and airway reactivity is studied between pulmonary function tests that are made before bariatric surgery.

location_facility: Department of Physiology, Hôpital Européen Georges Pompidou


title: Randomized Study Comparing Endovascular Repair Versus Conventional Repair for Ruptured Aorta-iliac Aneurysms

acronym: ECAR

summary: The aim of this multicenter randomized trial is to compare the endovascular repair versus conventional repair for ruptured aorta-iliac aneurysms observed on CT scan in stable patients with suitable anatomy. The main awaited result is the significant reduction of the mortality of the conventional repair.

ReferenceType: background

ReferenceCitation: Alsac JM, Desgranges P, Kobeiter H, Becquemin JP. Emergency endovascular repair for ruptured abdominal aortic aneurysms: feasibility and comparison of early results with conventional open repair. Eur J Vasc Endovasc Surg. 2005 Dec;30(6):632-9. Epub 2005 Aug 1.

ReferenceCitation: Desgranges P, Kobeiter H, Katsahian S, Bouffi M, Gouny P, Favre JP, Alsac JM, Sobocinski J, Julia P, Alimi Y, Steinmetz E, Haulon S, Alric P, Canaud L, Castier Y, Jean-Baptiste E, Hassen-Khodja R, Lermusiaux P, Feugier P, Destrieux-Garnier L, Charles-Nelson A, Marzelle J, Majewski M, Bourmaud A, Becquemin JP; ECAR Investigators. Editor's Choice - ECAR (Endovasculaire ou Chirurgie dans les Anévrysmes aorto-iliaques Rompus): A French Randomized Controlled Trial of Endovascular Versus Open Surgical Repair of Ruptured Aorto-iliac Aneurysms. Eur J Vasc Endovasc Surg. 2015 Sep;50(3):303-10. doi: 10.1016/j.ejvs.2015.03.028. Epub 2015 May 20.

family: Desgranges

full_name: P. Desgranges

given: P.

family: Kobeiter

full_name: H. Kobeiter

given: H.

family: Katsahian

full_name: S. Katsahian

given: S.

family: Bouffi

full_name: M. Bouffi

given: M.

family: Gouny

full_name: P. Gouny

family: Favre

full_name: J.-P. Favre

family: Alsac

full_name: J.M. Alsac

family: Sobocinski

full_name: J. Sobocinski

given: J.

family: Julia

full_name: P. Julia

family: Alimi

full_name: Y. Alimi

given: Y.

family: Steinmetz

full_name: E. Steinmetz

given: E.

family: Haulon

full_name: S. Haulon

family: Alric

full_name: P. Alric

family: Canaud

full_name: L. Canaud

given: L.

family: Castier

full_name: Y. Castier

family: Jean-Baptiste

full_name: E. Jean-Baptiste

family: Hassen-Khodja

full_name: R. Hassen-Khodja

given: R.

family: Lermusiaux

full_name: P. Lermusiaux

family: Feugier

full_name: P. Feugier

family: Destrieux-Garnier

full_name: L. Destrieux-Garnier

family: Charles-Nelson

full_name: A. Charles-Nelson

given: A.

family: Marzelle

full_name: J. Marzelle

family: Majewski

full_name: M. Majewski

family: Bourmaud

journal_name: European Journal of Vascular and Endovascular Surgery

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inria

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Diderot

title: Editor's Choice – ECAR (Endovasculaire ou Chirurgie dans les Anévrysmes aorto-iliaques Rompus): A French Randomized Controlled Trial of Endovascular Versus Open Surgical Repair of Ruptured Aorto-iliac Aneurysms

ReferenceCitation: Desgranges P, Kobeiter H, Castier Y, Sénéchal M, Majewski M, Krimi A. The Endovasculaire vs Chirurgie dans les Anévrysmes Rompus PROTOCOL trial update. J Vasc Surg. 2010 Jan;51(1):267-70. doi: 10.1016/j.jvs.2009.10.128.


title: Viral Infection of Lymphoid Cells Occuring at the First Manifestation of Idiopathic Nephrotic Syndrome

acronym: Nephrovir

summary: The primary purpose of the study is to evaluate the association of a latent infection of lymphoid cells during the first manifestation of steroid sensitive nephrite syndrome. The thirty nine units of general pediatrics and pediatric nephrite covering the parisian area will participate to the study. We speculate that hybridization of the genome, or a part of the genome, of a virus in lymphoid cells is responsible specific changes of genes expression, leading to the development of the disease.

ReferenceType: result

ReferenceCitation: Sellier-Leclerc AL, Duval A, Riveron S, Macher MA, Deschenes G, Loirat C, Verpont MC, Peuchmaur M, Ronco P, Monteiro RC, Haddad E. A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol. 2007 Oct;18(10):2732-9. Epub 2007 Sep 12.

ReferenceCitation: Ulinski T, Perrin L, Guigonis V, Driss F, Deschênes G, Bensman A. Remission of steroid- and CyA-resistant nephrotic syndrome using multiple drug immunosuppression. Pediatr Nephrol. 2007 Oct;22(10):1723-6. Epub 2007 Jul 17.

ReferenceCitation: Doucet A, Favre G, Deschênes G. Molecular mechanism of edema formation in nephrotic syndrome: therapeutic implications. Pediatr Nephrol. 2007 Dec;22(12):1983-90. Epub 2007 Jun 7. Review.

ReferenceCitation: Lorton F, Raynot J, Letavernier B, Isapof A, Debiec H, Pressac M, Deschênes G, Lenoir M, Ross-Cerdan L, Grapin C, Bensman A, Ulinski T. Gross proteinuria post transplant in a child with nephrotic syndrome of the Finnish type--mechanical vs immunological pathogenesis. Nephrol Dial Transplant. 2006 Dec;21(12):3579-82. Epub 2006 Aug 25.

ReferenceCitation: Lourdel S, Loffing J, Favre G, Paulais M, Nissant A, Fakitsas P, Créminon C, Féraille E, Verrey F, Teulon J, Doucet A, Deschênes G. Hyperaldosteronemia and activation of the epithelial sodium channel are not required for sodium retention in puromycin-induced nephrosis. J Am Soc Nephrol. 2005 Dec;16(12):3642-50. Epub 2005 Nov 2.

ReferenceCitation: Nathanson S, Cochat P, André JL, Guyot C, Loirat C, Nivet H, Deschênes G. Recurrence of nephrotic syndrome after renal transplantation: influence of increased immunosuppression. Pediatr Nephrol. 2005 Dec;20(12):1801-4. Epub 2005 Oct 14.

ReferenceCitation: Mansour H, Cheval L, Elalouf JM, Aude JC, Alyanakian MA, Mougenot B, Doucet A, Deschênes G. T-cell transcriptome analysis points up a thymic disorder in idiopathic nephrotic syndrome. Kidney Int. 2005 Jun;67(6):2168-77.

ReferenceCitation: Frange P, Frey MA, Deschênes G. [Immunity and immunosuppression in childhood idiopathic nephrotic syndrome]. Arch Pediatr. 2005 Mar;12(3):305-15. Review. French.

ReferenceCitation: Deschênes G, Feraille E, Doucet A. [Cellular and molecular mechanisms of sodium pump activation in experimental models of nephrotic syndrome]. Nephrologie. 2003;24(3):121-6. French.

ReferenceCitation: Féraille E, Mordasini D, Gonin S, Deschênes G, Vinciguerra M, Doucet A, Vandewalle A, Summa V, Verrey F, Martin PY. Mechanism of control of Na,K-ATPase in principal cells of the mammalian collecting duct. Ann N Y Acad Sci. 2003 Apr;986:570-8. Review.

ReferenceCitation: Debiec H, Guigonis V, Mougenot B, Haymann JP, Bensman A, Deschênes G, Ronco PM. Antenatal membranous glomerulonephritis with vascular injury induced by anti-neutral endopeptidase antibodies: toward new concepts in the pathogenesis of glomerular diseases. J Am Soc Nephrol. 2003 Jun;14 Suppl 1:S27-32. Review.

ReferenceCitation: Deschênes G, Feraille E, Doucet A. Mechanisms of oedema in nephrotic syndrome: old theories and new ideas. Nephrol Dial Transplant. 2003 Mar;18(3):454-6.

ReferenceCitation: Nathanson S, Lucidarme N, Landman-Parker J, Deschênes G. Long-term survival of renal graft complicated with Burkitt lymphoma. Pediatr Nephrol. 2002 Dec;17(12):1066-8. Epub 2002 Oct 8.

ReferenceCitation: Deschenes G. [LMXb1 generates the morphology of podocytes]. Arch Pediatr. 2002 Sep;9(9):1002-3. French.


title: ANRS HC 21 VASCU IL-2, Evaluation of the Cellular Immune Response, Clinical Efficacy and Tolerance After IL-2 Therapy in HCV-related Vasculitis Patients, Resistant to Conventional Therapy.

summary: A systemic Vasculitis is found in 5 to 10% of HCV infected patients with mixed cryoglobulinemia (MC). It mainly involves the skin, peripheral nerve and the kidney and may be life threatening. Twenty to 30% of HCV-MC Vasculitis patients are resistant to conventional therapy (i.e. antiviral therapy and/or immunosuppressors) and still have an active disease. Thus, new therapeutic approaches are necessary in such patients. We recently described a regulatory T cell (Treg) deficiency in HCV-related Vasculitis patients. Immunomodulatory effects of interleukin-2 (IL-2) are well established, notably the preferential expansion of Treg able to suppress inflammatory responses mediated by CD4+ and CD8+ T cells.

ReferenceCitation: Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, Klatzmann D. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011 Dec 1;365(22):2067-77. doi: 10.1056/NEJMoa1105143. Erratum in: N Engl J Med. 2014 Feb 20;370(8):786.

family: Saadoun

full_name: David Saadoun

given: David

family: Rosenzwajg

full_name: Michelle Rosenzwajg

given: Michelle

family: Joly

full_name: Florence Joly

given: Florence

family: Six

full_name: Adrien Six

given: Adrien

family: Carrat

full_name: Fabrice Carrat

given: Fabrice

family: Thibault

full_name: Vincent Thibault

given: Vincent

family: Sene

full_name: Damien Sene

given: Damien

family: Cacoub

full_name: Patrice Cacoub

given: Patrice

family: Klatzmann

full_name: David Klatzmann

journal_name: New England Journal of Medicine

publisher: Massachusetts Medical Society

publisher_dissemination: Massachusetts Medical Society

publisher_group: Massachusetts Medical Society

publisher_normalized: Massachusetts Medical Society

title: Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

lead_sponsor: French National Agency for Research on AIDS and Viral Hepatitis


title: Evaluation of the Initiation of Insulin Treatment Using Insulin Aspart on Blood Glucose Profile in Type 2 Diabetes Mellitus

summary: This trial is conducted in Europe. The aim of this trial is to investigate if using insulin aspart as start therapy will improve the efficacy on daytime blood glucose cycle profile in subjects with type 2 diabetes.

study_start_date_type: Actual

lead_sponsor: Novo Nordisk A/S


title: Target-Controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by the Index Bispectral: Comparison Between Manual Perfusion and Automated Perfusion During Rigid Bronchoscopy

summary: The purpose of this study is to compare manual administration of propofol and remifentanil and dual closed-loop using bispectral index as the control variable during rigid bronchoscopy.

ReferenceCitation: Liu N, Chazot T, Trillat B, Pirracchio R, Law-Koune JD, Barvais L, Fischler M. Feasibility of closed-loop titration of propofol guided by the Bispectral Index for general anaesthesia induction: a prospective randomized study. Eur J Anaesthesiol. 2006 Jun;23(6):465-9.

ReferenceCitation: Liu N, Chazot T, Genty A, Landais A, Restoux A, McGee K, Laloë PA, Trillat B, Barvais L, Fischler M. Titration of propofol for anesthetic induction and maintenance guided by the bispectral index: closed-loop versus manual control: a prospective, randomized, multicenter study. Anesthesiology. 2006 Apr;104(4):686-95.

ReferenceCitation: Liu N, Pruszkowski O, Leroy JE, Chazot T, Trillat B, Colchen A, Gonin F, Fischler M. Automatic administration of propofol and remifentanil guided by the bispectral index during rigid bronchoscopic procedures: a randomized trial. Can J Anaesth. 2013 Sep;60(9):881-7. doi: 10.1007/s12630-013-9986-7. Epub 2013 Jul 16.

family: Liu

full_name: Ngai Liu

given: Ngai

family: Pruszkowski

full_name: Olivier Pruszkowski

given: Olivier

family: Leroy

full_name: Jérôme Erwan Leroy

given: Jérôme Erwan

family: Chazot

full_name: Thierry Chazot

given: Thierry

family: Trillat

full_name: Bernard Trillat

given: Bernard

family: Colchen

full_name: Arlette Colchen

given: Arlette

family: Gonin

full_name: François Gonin

given: François

family: Fischler

full_name: Marc Fischler

given: Marc

journal_name: Canadian Journal of Anesthesia/Journal canadien d'anesthésie

lead_sponsor: Hopital Foch

intervention_type: Device


title: Nasal Epithelium Gene Expression Profiling in Child Respiratory Allergic

summary:
Using a human pangenomic microarray, the researchers established expression profiles of nasal epithelial cells, collected by brushing of patients belonging to one of four distinct groups:

allergic rhinitis to dust mite (AR) isolated (n=12),
AR associated with bronchial hyperreactivity (n=12),
AR associated with asthma (n=14),
control (n=14).

primary_purpose: Screening

ReferenceCitation: Giovannini-Chami L, Marcet B, Moreilhon C, Chevalier B, Illie MI, Lebrigand K, Robbe-Sermesant K, Bourrier T, Michiels JF, Mari B, Crénesse D, Hofman P, de Blic J, Castillo L, Albertini M, Barbry P. Distinct epithelial gene expression phenotypes in childhood respiratory allergy. Eur Respir J. 2012 May;39(5):1197-205. doi: 10.1183/09031936.00070511. Epub 2011 Oct 17.

family: Giovannini-Chami

full_name: Lisa Giovannini-Chami

given: Lisa

family: Marcet

full_name: Brice Marcet

given: Brice

family: Moreilhon

full_name: Chimène Moreilhon

given: Chimène

family: Chevalier

full_name: Benoît Chevalier

given: Benoît

family: Illie

full_name: Marius I. Illie

given: Marius I.

family: Lebrigand

full_name: Kévin Lebrigand

given: Kévin

family: Robbe-Sermesant

full_name: Karine Robbe-Sermesant

given: Karine

family: Bourrier

full_name: Thierry Bourrier

family: Michiels

full_name: Jean-François Michiels

given: Jean-François

family: Mari

full_name: Bernard Mari

family: Crénesse

full_name: Dominique Crénesse

given: Dominique

family: Hofman

full_name: Paul Hofman

given: Paul

family: de Blic

full_name: Jacques de Blic

given: Jacques

family: Castillo

full_name: Laurent Castillo

given: Laurent

family: Albertini

full_name: Marc Albertini

family: Barbry

full_name: Pascal Barbry

given: Pascal

journal_name: European Respiratory Journal

oa_colors: green hybrid

evidence: oa repository (via OAI-PMH title and first author match)

repository_institution: The Pennsylvania State University - CiteSeer X

repository_normalized: CiteSeerX

publisher: European Respiratory Society (ERS)

publisher_dissemination: European Respiratory Society

publisher_group: European Respiratory Society

publisher_normalized: European Respiratory Society

lead_sponsor: Centre Hospitalier Universitaire de Nice

location_facility: Department of Pediatrics, Nice University Hospital


title: Value of a Mobile Team of Cardiologist Using Echocardiography for Managing Patients With Acute Heart Failure

acronym: EMEPIC

summary: The aim of the study is to compare clinical management of patients with acute decompensation of heart failure, hospitalized in non cardiological ward, with the use of a mobile team including a cardiologist with portable echocardiography and standard care. The hypothesis is that a mobile team will lead to shorter hospitalization.

primary_purpose: Diagnostic

lead_sponsor: University Paris 7 - Denis Diderot


title: Ropivacaine 0.75% vs Ropivacaine 0.75% Plus Mepivacaine 1.5% for Subgluteal Sciatic Bloc: a Prospective Double Blind Randomized Controlled Study

summary:
In loco regional anesthesia, much more than for general anesthesia, the choice of the product is largely left at the discretion of the practitioner. Two categories of local anesthetics are distinguished according to their pharmacodynamic characteristics: products with a short time of installation and a short duration period, and products with a longer delay of installation of the sensitive and motor block, but with a long-term duration. Indeed, the combined use of two products pharmacodynamically different seems to be of a practical interest.

This study provides a comparison of the onset of action of 30 ml of ropivacaine 0.75% and 30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5% for the subgluteal sciatic nerve block. This is a prospective randomized double-blind study where the main criterion of judgment is the time of installation of a sensitive block compatible with surgery in the sciatic territory nerve. Fifteen patients per group were calculated to detect a 50% decrease of the onset of action in the combination group with a power of 90% and alpha to 5%, according to a previous pilot study. The secondary endpoints are the intensity and time of installation of the motor block, the duration of sensitive and motor block, the total dose of morphine administered within 48 hours, as well as its possible side effects.

lead_sponsor: Centre Hospitalier Universitaire, Amiens

location_facility: CHU d'Amiens, Pole Anesthesie Réanimation, Place Victor Pauchet


type: Other Identifier

title: Randomized Phase-III Trial Comparing Fludarabine and Cyclophosphamide Plus Rituximab (FCR) to FC and MabCampath (FCCam) for Previously Untreated Fit Patients With Chronic Lymphocytic Leukemia (CLL)

summary:
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to kill cancer cells or stop them from growing. Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. It is not yet known whether giving fludarabine and cyclophosphamide together with rituximab is more effective than giving fludarabine and cyclophosphamide together with alemtuzumab in treating B-cell chronic lymphocytic leukemia.

PURPOSE: This randomized phase III trial is studying giving fludarabine together with cyclophosphamide and rituximab to see how well it works as first-line therapy compared with giving fludarabine together with cyclophosphamide and alemtuzumab in treating patients with B-cell chronic lymphocytic leukemia.

ReferenceCitation: Grgurevic S, Montilla-Perez P, Bradbury A, Gilhodes J, Queille S, Pelofy S, Bancaud A, Filleron T, Ysebaert L, Récher C, Laurent G, Fournié JJ, Cazaux C, Quillet-Mary A, Hoffmann JS. DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status. Haematologica. 2018 Jun;103(6):1038-1046. doi: 10.3324/haematol.2017.174243. Epub 2018 Mar 22.

family: Grgurevic

full_name: Srdana Grgurevic

given: Srdana

family: Montilla-Perez

full_name: Patricia Montilla-Perez

given: Patricia

family: Bradbury

full_name: Alice Bradbury

given: Alice

family: Gilhodes

full_name: Julia Gilhodes

given: Julia

family: Queille

full_name: Sophie Queille

given: Sophie

family: Pelofy

full_name: Sandrine Pelofy

given: Sandrine

family: Bancaud

full_name: Aurélien Bancaud

given: Aurélien

family: Filleron

full_name: Thomas Filleron

given: Thomas

family: Ysebaert

full_name: Loïc Ysebaert

given: Loïc

family: Récher

full_name: Christian Récher

given: Christian

family: Laurent

full_name: Guy Laurent

given: Guy

family: Fournié

full_name: Jean-Jacques Fournié

given: Jean-Jacques

family: Cazaux

full_name: Christophe Cazaux

given: Christophe

family: Quillet-Mary

full_name: Anne Quillet-Mary

given: Anne

family: Hoffmann

full_name: Jean-Sébastien Hoffmann

given: Jean-Sébastien

license: cc-by-nc

license_normalized: cc-by-nc

publisher_dissemination: Ferrata Storti Foundation (Haematologica)

ReferenceCitation: Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012 May 31;119(22):5104-10. doi: 10.1182/blood-2011-07-365437. Epub 2012 Feb 14.

name: Service d'Hématologie, Centre Henri Becquerel, Rouen, France;

family: Lepretre

full_name: Stephane Lepretre

given: Stephane

name: Service d'Hématologie, Institut Paoli Calmette, Marseille, France;

family: Aurran

full_name: Therese Aurran

name: Service d'Hématologie, Centre Hospitalier Universitaire (CHU), Nantes, France;

name: Service d'Hématologie, CHU, Lille, France;

name: Service d'Hématologie, CHU, Clermont-Ferrand, France;

name: Service d'Onco-Hématologie, Centre Hospitalier, La Roche Sur Yon, France;

name: Service d'Hématologie, CHU, Dijon, France;

name: Service d'Hématologie, CHU, Reims, France;

name: Service d'Hématologie, Hôpital de la Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France;

name: Service d'Hématologie, CHU, Amiens, France;

name: Service d'Hématologie, Centre Hospitalier, Annecy, France;

name: Centre d'Investigation Clinique, Hôpital Saint Louis, Paris, France;

name: Service d'Hématologie, CHU, Tours, France;

name: Service d'Hématologie, Cliniques Universitaires, Cliniques Universitaires Saint-Luc, Brussels, Belgium;

name: Laboratoire d'Immunologie et EA 4369, Faculté de Médecine, Nancy-Université, Vandœuvre-lès-Nancy, France;

name: Laboratoire d'Hématologie, CHU, Inserm U978, Avicenne, France; and

name: Pôle Hématologie, CHU et EA 4369, Faculté de Médecine, Nancy-Université, Vandœuvre-lès-Nancy, France


title: Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis

summary:
PET imaging of activated microglia offers a tool of investigation of a range of brain diseases where neuroinflammation is a component.

Amyotrophic lateral sclerosis is the most frequent motoneuronal disease in adult.

This study was designed to explore the feasibility of molecular imaging modality by Positron Emission Tomography using 18F-X as an in vivo marker of activated microglia for the assessment of neuroinflammation in amyotrophic lateral sclerosis.

PET may help in the diagnosis of the disease and, further, may allow assessment of the efficacy of antiinflammatory treatment.

ReferenceCitation: Kassiou M, Meikle SR, Banati RB. Ligands for peripheral benzodiazepine binding sites in glial cells. Brain Res Brain Res Rev. 2005 Apr;48(2):207-10. Epub 2005 Jan 22. Review.

ReferenceCitation: Banati RB. Visualising microglial activation in vivo. Glia. 2002 Nov;40(2):206-17. Review.

ReferenceCitation: Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH, Perkin GD, Smith T, Hewson AK, Bydder G, Kreutzberg GW, Jones T, Cuzner ML, Myers R. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. 2000 Nov;123 ( Pt 11):2321-37.

ReferenceCitation: Zhang MR, Kumata K, Maeda J, Yanamoto K, Hatori A, Okada M, Higuchi M, Obayashi S, Suhara T, Suzuki K. 11C-AC-5216: a novel PET ligand for peripheral benzodiazepine receptors in the primate brain. J Nucl Med. 2007 Nov;48(11):1853-61.

ReferenceCitation: Zhang MR, Maeda J, Ogawa M, Noguchi J, Ito T, Yoshida Y, Okauchi T, Obayashi S, Suhara T, Suzuki K. Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain. J Med Chem. 2004 Apr 22;47(9):2228-35.

ReferenceCitation: Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, Nicolas G, Venel Y, Hommet C, Baulieu JL, Cottier JP, Roussel C, Kassiou M, Guilloteau D, Ribeiro MJ. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2012;7(12):e52941. doi: 10.1371/journal.pone.0052941. Epub 2012 Dec 31.

family: Corcia

full_name: Philippe Corcia

given: Philippe

family: Tauber

full_name: Clovis Tauber

given: Clovis

family: Vercoullie

full_name: Johnnie Vercoullie

given: Johnnie

family: Arlicot

full_name: Nicolas Arlicot

given: Nicolas

family: Prunier

full_name: Caroline Prunier

given: Caroline

family: Praline

full_name: Julien Praline

given: Julien

family: Nicolas

full_name: Guillaume Nicolas

given: Guillaume

family: Venel

full_name: Yann Venel

given: Yann

family: Hommet

full_name: Caroline Hommet

family: Baulieu

full_name: Jean-Louis Baulieu

given: Jean-Louis

family: Cottier

full_name: Jean-Philippe Cottier

given: Jean-Philippe

family: Roussel

full_name: Catherine Roussel

given: Catherine

family: Kassiou

full_name: Mickael Kassiou

given: Mickael

family: Guilloteau

full_name: Denis Guilloteau

given: Denis

family: Ribeiro

full_name: Maria-Joao Ribeiro

given: Maria-Joao

repository_institution: CERN European Organization for Nuclear Research - Zenodo

repository_normalized: Zenodo

repositories:
PubMed Central
Zenodo
pdfs.semanticscholar.org

title: Molecular Imaging of Microglial Activation in Amyotrophic Lateral Sclerosis

location_facility: Service de Médecine Nucléaire et Ultrasons - Hôpital Bretonneau


title: Catheters Dysfunction Rate After Instillation of Ethanol 60% Lock Solution in Tunneled Silicone Catheter of Chronic Hemodialysis Patients

acronym: Ethanol

summary:
The primary objective of the study is to examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis.

The catheters dysfunction rate is the primary outcome. The dysfunction is defined as partial or complete occlusion or infection associated with dialysis catheter.

As a secondary outcome, the dialysis quality is also examined (urea reduction rate, total ultrafiltration)

ReferenceCitation: Coupez E, Timsit JF, Ruckly S, Schwebel C, Gruson D, Canet E, Klouche K, Argaud L, Bohe J, Garrouste-Orgeas M, Mariat C, Vincent F, Cayot S, Cointault O, Lepape A, Darmon M, Boyer A, Azoulay E, Bouadma L, Lautrette A, Souweine B. Guidewire exchange vs new site placement for temporary dialysis catheter insertion in ICU patients: is there a greater risk of colonization or dysfunction? Crit Care. 2016 Jul 30;20(1):230. doi: 10.1186/s13054-016-1402-6.

family: Coupez

full_name: Elisabeth Coupez

given: Elisabeth

family: Timsit

full_name: Jean-François Timsit

given: Jean-François

family: Ruckly

full_name: Stéphane Ruckly

given: Stéphane

family: Schwebel

full_name: Carole Schwebel

given: Carole

family: Gruson

full_name: Didier Gruson

given: Didier

family: Canet

full_name: Emmanuel Canet

given: Emmanuel

family: Klouche

full_name: Kada Klouche

given: Kada

family: Argaud

full_name: Laurent Argaud

given: Laurent

family: Bohe

full_name: Julien Bohe

family: Garrouste-Orgeas

full_name: Maïté Garrouste-Orgeas

given: Maïté

family: Mariat

full_name: Christophe Mariat

given: Christophe

family: Vincent

full_name: François Vincent

given: François

family: Cayot

full_name: Sophie Cayot

given: Sophie

family: Cointault

full_name: Olivier Cointault

given: Olivier

family: Lepape

full_name: Alain Lepape

given: Alain

family: Darmon

full_name: Michael Darmon

given: Michael

family: Boyer

full_name: Alexandre Boyer

given: Alexandre

family: Azoulay

full_name: Elie Azoulay

given: Elie

family: Bouadma

full_name: Lila Bouadma

given: Lila

family: Lautrette

full_name: Alexandre Lautrette

family: Souweine

full_name: Bertrand Souweine

given: Bertrand


title: Closure of Patent Foramen Ovale or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence

acronym: CLOSE

summary:
A patent foramen ovale (PFO) is found more frequently in patients with an ischemic stroke than in control subjects.

Therapeutic options to prevent stroke recurrence include antiplatelet drugs, oral anticoagulants, and transcatheter closure of the foramen. However, there are no published studies showing convincingly the superiority of any one of these strategies in preventing stroke recurrence.

The aim of this randomized clinical trial is to assess whether chronic anticoagulation on the one hand and transcatheter on the other hand are superior to chronic antiplatelet therapy in preventing stroke recurrence.

primary_purpose: Prevention

ReferenceCitation: Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, Béjot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaduva C, Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, Robinet-Borgomano E, Sablot D, Lacour JC, Zuber M, Favrole P, Pinel JF, Apoil M, Reiner P, Lefebvre C, Guérin P, Piot C, Rossi R, Dubois-Randé JL, Eicher JC, Meneveau N, Lusson JR, Bertrand B, Schleich JM, Godart F, Thambo JB, Leborgne L, Michel P, Pierard L, Turc G, Barthelet M, Charles-Nelson A, Weimar C, Moulin T, Juliard JM, Chatellier G; CLOSE Investigators. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017 Sep 14;377(11):1011-1021. doi: 10.1056/NEJMoa1705915.

family: Mas

full_name: Jean-Louis Mas

given: Jean-Louis

family: Derumeaux

full_name: Geneviève Derumeaux

given: Geneviève

family: Guillon

full_name: Benoît Guillon

given: Benoît

family: Massardier

full_name: Evelyne Massardier

given: Evelyne

family: Hosseini

full_name: Hassan Hosseini

given: Hassan

family: Mechtouff

full_name: Laura Mechtouff

given: Laura

family: Arquizan

full_name: Caroline Arquizan

given: Caroline

family: Béjot

full_name: Yannick Béjot

given: Yannick

family: Vuillier

full_name: Fabrice Vuillier

given: Fabrice

family: Detante

full_name: Olivier Detante

family: Guidoux

full_name: Céline Guidoux

given: Céline

family: Canaple

full_name: Sandrine Canaple

given: Sandrine

family: Vaduva

full_name: Claudia Vaduva

given: Claudia

family: Dequatre-Ponchelle

full_name: Nelly Dequatre-Ponchelle

given: Nelly

family: Sibon

full_name: Igor Sibon

given: Igor

family: Garnier

full_name: Pierre Garnier

given: Pierre

family: Ferrier

full_name: Anna Ferrier

given: Anna

family: Timsit

full_name: Serge Timsit

given: Serge

family: Robinet-Borgomano

full_name: Emmanuelle Robinet-Borgomano

given: Emmanuelle

family: Sablot

full_name: Denis Sablot

given: Denis

family: Lacour

full_name: Jean-Christophe Lacour

given: Jean-Christophe

family: Zuber

full_name: Mathieu Zuber

given: Mathieu

family: Favrole

full_name: Pascal Favrole

given: Pascal

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - UFC - Université de Franche-Comté

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Université de Nantes

ReferenceCitation: Turc G, Lee JY, Brochet E, Kim JS, Song JK, Mas JL; CLOSE and DEFENSE-PFO Trial Investigators. Atrial Septal Aneurysm, Shunt Size, and Recurrent Stroke Risk in Patients With Patent Foramen Ovale. J Am Coll Cardiol. 2020 May 12;75(18):2312-2320. doi: 10.1016/j.jacc.2020.02.068.

journal_name: Journal of the American College of Cardiology

ReferenceCitation: Turc G, Calvet D, Guérin P, Sroussi M, Chatellier G, Mas JL; CLOSE Investigators. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study. J Am Heart Assoc. 2018 Jun 17;7(12). pii: e008356. doi: 10.1161/JAHA.117.008356.

name: Department of Neurology Hôpital Sainte‐Anne Paris France

name: Université Paris Descartes Sorbonne Paris Cité Paris France

name: Department of Cardiology INSERM UMR 915 Institut du Thorax Nantes France

name: Institut du Thorax Centre Hospitalier Universitaire de Nantes Nantes France

name: Department of Cardiology Cochin Hospital APHP Paris France

name: Epidemiology and Clinical Research Unit Georges Pompidou European Hospital APHP Paris France

journal_name: Journal of the American Heart Association

title: Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta‐Analysis, and New Insights From the CLOSE Study

ReferenceCitation: Mas JL, Derumeaux G, Amarenco P, Arquizan C, Aubry P, Barthelet M, Bertrand B, Brochet E, Cabanes L, Donal E, Dubois-Randé JL, Durand-Zaleski I, Ernande L, Finet G, Fraisse A, Giroud M, Guérin P, Habib G, Juliard JM, Leys D, Lièvre M, Lusson JR, Marcon F, Michel P, Moulin T, Mounier-Vehier F, Pierard L, Piot C, Rey C, Rodier G, Roudaut R, Schleich JM, Teiger E, Turc G, Vuillier F, Weimar C, Woimant F, Chatellier G; CLOSE investigators. close: Closure of patent foramen ovale, oral anticoagulants or antiplatelet therapy to prevent stroke recurrence: Study design. Int J Stroke. 2016 Aug;11(6):724-32. doi: 10.1177/1747493016643551. Epub 2016 Apr 7.

name: Department of Neurology, Sainte-Anne Hospital, Paris Descartes University, Inserm 894, DHU NeuroVasc, Paris, France

name: Department of Physiology, Henri Mondor Hospital, Paris Est Créteil University, Inserm 955, DHU ATVB, Créteil, France

name: APHP, Department of Neurology and Stroke Center, Bichat Hospital, Paris-Diderot University, Inserm 1148, DHU FIRE, Paris, France

name: Department of Neurology, Gui de Chauliac Hospital, Montpellier, France

name: APHP, Department of Cardiology, Bichat Hospital, Paris Diderot University, Inserm 1148, DHU FIRE, Paris, France

name: Department of Cardiovascular Investigations, Louis Pradel Hospital, Lyon University, Bron, France

name: Department of Cardiology, CHU A. Michallon, Joseph Fourier University, Grenoble, France

name: AP-HP, Department of Cardiology, Cochin Hospital, Paris-Descartes University, Paris, France

name: Department of Cardiology and Vascular Diseases, Pontchaillou Hospital, Rennes University, Rennes, France

name: APHP, Department of Cardiology, Henri-Mondor Hospital, Paris Est Créteil University, Inserm 955, DHU ATVB, Créteil, France

name: AP-HP, Department of Public Health, Henri Mondor Hospital, Paris Est Créteil University, Créteil, France

name: Department of Cardiology, Cardiovascular Hospital, Claude Bernard University, Inserm 1060, Lyon, France

name: Department of Pediatric Cardiology, La Timone Hospital, Aix-Marseille Université, Marseille, France

name: Department of Neurology, CHU Dijon, Bourgogne University, Dijon Stroke Registry, Dijon France

name: Department of Cardiology, Institut du Thorax, CHU Nantes, Nantes, France

name: Department of Cardiology, La Timone Hospital, Aix-Marseille Université, Marseille France

name: Department of Neurology and Stroke Unit, Roger Salengro Hospital, Lille 2 University, Inserm 1171, Lille, France

name: UMR CNRS 5558, Lyon 1 University, Lyon, France

name: Department of Cardiology and Vascular Diseases, Gabriel Montpied Hospital, Auvergne University, UMR 6284 Clermont-Ferrand, France

name: Department of Cardiovascular Diseases, Pediatric Cardiology Unit, Nancy University, Nancy, France

name: Stroke Center, Department of Neurology, Centre Hospitalier Universitaire Vaudois and Lausanne University, Lausanne, Switzerland

name: Department of Neurology, CHU Besancon, Franche-Comté University, CIC 1431, Besancon, France

name: Department of Neurology, Doctor Schaffner Hospital, Lens, France

name: Department of Cardiology, Sart Tilman Hospital, Liège University, Liège, Belgium

name: Department of Interventional Cardiology, Clinique du Millénaire, Montpellier University, UMR 5203, Montpellier, France

name: Department of Pediatric Cardiology, Cardiology Hospital, Lille 2 University, Lille, France

name: Department of Neurology, Annecy-Genevois Hospital, Annecy, France

name: Department of Cardiology and Vascular Diseases, Haut Leveque Hospital, Bordeaux University, Bordeaux, France

name: Department of Neurology, University Hospital, University of Duisburg-Essen, Essen, Germany

name: APHP, Department of Neurology, Lariboisière Hospital, Agence Régionale de Santé Île-de-France, Paris, France

name: APHP, Epidemiology and Clinical Research Unit, Georges Pompidou European hospital, Paris Descartes University, Paris, France


title: Benefit of Septifast Multiplex PCR in the Etiologic Diagnosis and Therapeutic Approach for Onco-hematology Patients Presenting Sepsis

acronym: SEPTIFAST

summary: A SpetiFast multiplex PCR kit has recently been placed on the market witch can evidence the DNA of 90% of micro-organisms (bacteria and fungus) implicated in sepsis. However, the clinical impact of being able to detect the DNA of these various agents is unknown. We propose to assess the benefit to patient care of the SeptiFast multiples PCR by answering three questions : 1/in patients with septic immunosuppression, does this kit evidence etiologic agents not revealed by classical methods? 2/Does the use of PCR results permit different diagnostic hypotheses to be considered? 3/Does having the SeptiFast results entail changes to the therapeutic plan?

lead_sponsor: University Hospital, Grenoble


title: Impact of Anti-TNF Antibodies on the T-lymphocyte and Macrophage Cooperation in the Crohn Disease

summary: The aim of this research is to study Crohn disease patients before and after anti-TNF, the cooperation between lamina propria T-lymphocytes and macrophages, through the expression of co-signalisation molecules and their ligands, the production of cytokines participating in this cooperation, and the potential role of regulatory T lymphocytes.

primary_purpose: Basic Science

ReferenceCitation: Puntis J, McNeish AS, Allan RN. Long term prognosis of Crohn's disease with onset in childhood and adolescence. Gut. 1984 Apr;25(4):329-36.

ReferenceCitation: Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther. 2000 Dec;14(12):1553-9.

ReferenceCitation: Arnott ID, Watts D, Satsangi J. Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol Res. 2003 Jan;47(1):1-10. Review.

ReferenceCitation: ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002 Feb;50(2):206-11.

ReferenceCitation: MacDonald TT, Di Sabatino A, Gordon JN. Immunopathogenesis of Crohn's disease. JPEN J Parenter Enteral Nutr. 2005 Jul-Aug;29(4 Suppl):S118-24; discussion S124-5, S184-8. Review. Erratum in: JPEN J Parenter Enteral Nutr. 2006 Jan-Feb;30(1):table of contents. DiSabatino, Antonio [corrected to Di Sabatino, Antonio].

ReferenceCitation: Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994 Oct;1(7):553-62.

ReferenceCitation: Noguchi M, Hiwatashi N, Liu Z, Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut. 1998 Aug;43(2):203-9.

ReferenceCitation: Itoh J, de La Motte C, Strong SA, Levine AD, Fiocchi C. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut. 2001 Jul;49(1):35-41.

ReferenceCitation: Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 1999 Jan;116(1):22-8.

ReferenceCitation: Filippi J, Mambrini P, Arab K, Schneider SM, Hébuterne X. [Treatment of oesophageal Crohn's disease by infliximab]. Gastroenterol Clin Biol. 2005 Jan;29(1):84-5. French.

ReferenceCitation: Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, Otsuka J, Okamura S, Fujita S, Harada M. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology. 2005 Feb;128(2):376-92.

ReferenceCitation: Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine. 2001 Aug 21;15(4):212-22.

ReferenceCitation: Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001 Nov;121(5):1145-57.

ReferenceCitation: Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Piqué JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol. 2006 Feb 15;176(4):2617-24.

ReferenceCitation: Filippi J, Roger PM, Schneider SM, Durant J, Breittmayer JP, Benzaken S, Bernard A, Dellamonica P, Hébuterne X; Groupe d'Etude Niçois Polyvalent en Infectiologie (GENPI). Infliximab and human immunodeficiency virus infection: Viral load reduction and CD4+ T-cell loss related to apoptosis. Arch Intern Med. 2006 Sep 18;166(16):1783-4.

ReferenceCitation: Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, Nakamura T, Koganei K, Fukushima T, Watanabe M. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol. 2004 Sep 1;173(5):3119-30.

ReferenceCitation: Kelsen J, Agnholt J, Hoffmann HJ, Rømer JL, Hvas CL, Dahlerup JF. FoxP3(+)CD4(+)CD25(+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease. Clin Exp Immunol. 2005 Sep;141(3):549-57.

ReferenceCitation: Ochsenkühn T, Göke B, Sackmann M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol. 2002 Aug;97(8):2022-5.

ReferenceCitation: Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004 May;126(6):1593-610. Review.

location_facility: Fédération des Maladies de l'appareil Digestif et de la Nutrition


title: Frontline Therapy of Diffuse Large B Cell Lymphoma of the Adult ( 18 to 60 Years Old): Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14 -Rituximab. Multicentric Randomized Prospective Trial.

summary: The aim of the protocol is to compare the outcome of patients with DLBCL stage II bulky, III or IV with 1 to 3 adverse prognostic factors according to the International prognostic index. Patients with eligibility criteria and who gave informed consent will be randomised between CHOP-14- Rituximab x 8 courses and High dose chemotherapy with rituximab including autologous stem cell support. The aim of the study is to compare the Event free survival between the two arms and to gain insight into the prognostic significance of several biological markers gathered at the time of diagnosis/randomisation ( i.e. Fcgamma R III A genotyping, DNA profile and BCL é expression).


title: Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease

acronym: VOLCADREP

summary: Sickle cell disease (SCD) is the most common inherited disease of the world affecting African and Caribbean populations. SCD is caused by the homozygous inheritance of the gene for sickle hemoglobin (HbS). Most patients with SCD develop abnormal pulmonary function characterized by airway obstruction, restrictive lung disease, abnormal diffusing capacity, hypoxemia and pulmonary hypertension In healthy subjects, lung capillary blood volume (Qc) and membrane diffusing capacity (Dm) can be accurately measured by the nitric oxide-carbon monoxide (NO-CO) method. We propose to study, for the first time, lung capillary blood volume and alveolar membrane diffusing capacity, using the NO-CO method, in children with SCD aged of at least 6 years Early determination of lung function and pulmonary circulation in children with SCD is very important, not only for the understanding of physiopathologic mechanisms of the disease but also for a better therapeutic management of these children.


title: Phase II Study of the Predictive Value of the Expression of Tumoral MGMT With Respect to the Therapeutic Response of Fotemustine in Patients With Metastatic Malignant Melanoma

summary:
RATIONALE: Drugs used in chemotherapy, such as fotemustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.

PURPOSE: This phase II trial is studying fotemustine to see how well it works in treating patients with metastatic melanoma.

lead_sponsor: Institut du Cancer de Montpellier - Val d'Aurelle

location_facility: Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle


title: Effects of a Single Dose of Intrathecal Magnesium Sulfate on Postoperative Morphine Consumption After Total Hip Replacement

summary: Magnesium is implicated in the activation of NMDA receptors by amino-excitatory acids in the central nervous system [1]. Magnesium deficiency is associated to an increased activation of these receptors, and to an increased sensitivity to pain in animals. Spinal cord is the site of sensitization of pain, mainly mediated by the NMDA receptors, and intrathecal magnesium may have anti-hyperalgesic effect when administered intrathecally [2]. As intrathecal magnesium has already been used in humans for treatment of eclampsia, we stated that it could also improve postoperative analgesia and reduce the need for auto-administered morphine if given (50 mg of magnesium sulfate) with the intrathecal anesthetic drugs (bupivacaine and sufentanil) injected for orthopedic surgery.

ReferenceCitation: Mayer ML, Westbrook GL. Permeation and block of N-methyl-D-aspartic acid receptor channels by divalent cations in mouse cultured central neurones. J Physiol. 1987 Dec;394:501-27.

ReferenceCitation: Buvanendran A, McCarthy RJ, Kroin JS, Leong W, Perry P, Tuman KJ. Intrathecal magnesium prolongs fentanyl analgesia: a prospective, randomized, controlled trial. Anesth Analg. 2002 Sep;95(3):661-6, table of contents.


title: Phase 2 Study to Improve Tolerance of Chemotherapy Involving Cetuximab and Multidrug FOLFIRI, With Pharmacokinetic and Pharmacogenetic Studies, in Patients With Metastatic Colorectal Cancer

summary:
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cetuximab together with combination chemotherapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving cetuximab together with combination chemotherapy works in treating patients with advanced or metastatic colorectal cancer.

ReferenceCitation: Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord JP, Fonck M, Laurand A, Poirier AL, Morel A, Chatelut E, Robert J, Gamelin E. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer. 2008 Oct 21;99(8):1239-45. doi: 10.1038/sj.bjc.6604673. Epub 2008 Sep 16.

family: Rouits

full_name: E Rouits

given: E

family: Charasson

full_name: V Charasson

given: V

family: Pétain

full_name: A Pétain

given: A

family: Boisdron-Celle

full_name: M Boisdron-Celle

given: M

family: Delord

full_name: J-P Delord

given: J-P

family: Fonck

full_name: M Fonck

family: Laurand

full_name: A Laurand

family: Poirier

full_name: A-L Poirier

given: A-L

family: Morel

full_name: A Morel

family: Chatelut

full_name: E Chatelut

family: Robert

full_name: J Robert

given: J

family: Gamelin

full_name: E Gamelin

journal_name: British Journal of Cancer

evidence: open (via page says license)

license: cc-by-nc-sa

license_normalized: cc-by-nc-sa

license: implied-oa

license_normalized: implied-oa

ReferenceCitation: Rollin J, Payancé A, Gouilleux-Gruart V, Boisdron-Celle M, Azzopardi N, Morel A, Gruel Y, Paintaud G, Gamelin E, Watier H, Lecomte T. Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab. Pharmacogenomics. 2015 Dec;16(18):2035-43. doi: 10.2217/pgs.15.139. Epub 2015 Nov 30.

family: Rollin

full_name: Jérôme Rollin

given: Jérôme

family: Payancé

full_name: Audrey Payancé

given: Audrey

family: Gouilleux-Gruart

full_name: Valérie Gouilleux-Gruart

given: Valérie

full_name: Michelle Boisdron-Celle

given: Michelle

family: Azzopardi

title: Significant effect ofVEGFApolymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab


title: Phase 4 Study to Characterize and Evaluate Markers of Chemoresistance in Patients With Metastatic Colorectal Cancer

summary:
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer receiving chemotherapy may help doctors understand the effect of chemotherapy on biomarkers. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This phase IV trial is studying biomarkers in patients undergoing chemotherapy for metastatic colorectal cancer.

ReferenceCitation: Deyme L, Barbolosi D, Mbatchi LC, Tubiana-Mathieu N, Ychou M, Evrard A, Gattacceca F. Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen. Cancer Chemother Pharmacol. 2021 Aug;88(2):247-258. doi: 10.1007/s00280-021-04255-9. Epub 2021 Apr 28.

family: Deyme

full_name: Laure Deyme

given: Laure

family: Barbolosi

full_name: Dominique Barbolosi

given: Dominique

family: Mbatchi

full_name: Litaty Céphanoée Mbatchi

given: Litaty Céphanoée

family: Tubiana-Mathieu

full_name: Nicole Tubiana-Mathieu

given: Nicole

family: Ychou

full_name: Marc Ychou

given: Marc

family: Evrard

full_name: Alexandre Evrard

given: Alexandre

family: Gattacceca

full_name: Florence Gattacceca

given: Florence

journal_name: Cancer Chemotherapy and Pharmacology

publisher_dissemination: Springer-Nature

publisher_group: Springer-Nature

lead_sponsor: Centre Hospital Regional Universitaire de Limoges


title: The Role of Preoperative Oral Immunonutrition in Major Vascular Surgery

summary:
The role of preoperative oral immunonutrition in major vascular surgery.

The mean purpose of this study was to determine the prevalence of post-operative infection complications after major vascular surgery in group of patients with preoperative oral immunonutrition.

This group was compared to a control group.

Secondary purpose was to evaluate the effect of preoperative oral immunonutrition on postoperative mortality (30 days), the medium length of stay in the hospital and the cost of treatment in the two groups

ReferenceCitation: Gallagher-Allred CR, Voss AC, Finn SC, McCamish MA. Malnutrition and clinical outcomes: the case for medical nutrition therapy. J Am Diet Assoc. 1996 Apr;96(4):361-6, 369; quiz 367-8. Review.

ReferenceCitation: Bauer J, Capra S, Ferguson M. Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr. 2002 Aug;56(8):779-85.

ReferenceCitation: Hill GL, Blackett RL, Pickford I, Burkinshaw L, Young GA, Warren JV, Schorah CJ, Morgan DB. Malnutrition in surgical patients. An unrecognised problem. Lancet. 1977 Mar 26;1(8013):689-92.

ReferenceCitation: Arora NS, Rochester DF. Respiratory muscle strength and maximal voluntary ventilation in undernourished patients. Am Rev Respir Dis. 1982 Jul;126(1):5-8.

ReferenceCitation: Heymsfield SB, Bethel RA, Ansley JD, Gibbs DM, Felner JM, Nutter DO. Cardiac abnormalities in cachectic patients before and during nutritional repletion. Am Heart J. 1978 May;95(5):584-94.

ReferenceCitation: Reilly JJ Jr, Hull SF, Albert N, Waller A, Bringardener S. Economic impact of malnutrition: a model system for hospitalized patients. JPEN J Parenter Enteral Nutr. 1988 Jul-Aug;12(4):371-6.

ReferenceCitation: Gianotti L, Braga M, Nespoli L, Radaelli G, Beneduce A, Di Carlo V. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. Gastroenterology. 2002 Jun;122(7):1763-70.

ReferenceCitation: Gianotti L, Braga M, Frei A, Greiner R, Di Carlo V. Health care resources consumed to treat postoperative infections: cost saving by perioperative immunonutrition. Shock. 2000 Sep;14(3):325-30.

ReferenceCitation: Robinson G, Goldstein M, Levine GM. Impact of nutritional status on DRG length of stay. JPEN J Parenter Enteral Nutr. 1987 Jan-Feb;11(1):49-51.

ReferenceCitation: Chima CS, Barco K, Dewitt ML, Maeda M, Teran JC, Mullen KD. Relationship of nutritional status to length of stay, hospital costs, and discharge status of patients hospitalized in the medicine service. J Am Diet Assoc. 1997 Sep;97(9):975-8; quiz 979-80.

ReferenceCitation: Braunschweig C, Gomez S, Sheean PM. Impact of declines in nutritional status on outcomes in adult patients hospitalized for more than 7 days. J Am Diet Assoc. 2000 Nov;100(11):1316-22; quiz 1323-4.

ReferenceCitation: Lewis SJ, Egger M, Sylvester PA, Thomas S. Early enteral feeding versus "nil by mouth" after gastrointestinal surgery: systematic review and meta-analysis of controlled trials. BMJ. 2001 Oct 6;323(7316):773-6.

ReferenceCitation: Spark JI, Robinson JM, Gallavin L, Gough MJ, Homer-Vanniasinkam S, Kester RC, Scott DJ. Patients with chronic critical limb ischaemia have reduced total antioxidant capacity and impaired nutritional status. Eur J Vasc Endovasc Surg. 2002 Dec;24(6):535-9.

ReferenceCitation: Evoy D, Lieberman MD, Fahey TJ 3rd, Daly JM. Immunonutrition: the role of arginine. Nutrition. 1998 Jul-Aug;14(7-8):611-7. Review.

ReferenceCitation: Kirk SJ, Barbul A. Role of arginine in trauma, sepsis, and immunity. JPEN J Parenter Enteral Nutr. 1990 Sep-Oct;14(5 Suppl):226S-229S. Review.

ReferenceCitation: Wu D, Meydani SN. n-3 polyunsaturated fatty acids and immune function. Proc Nutr Soc. 1998 Nov;57(4):503-9. Review.

ReferenceCitation: Beale RJ, Bryg DJ, Bihari DJ. Immunonutrition in the critically ill: a systematic review of clinical outcome. Crit Care Med. 1999 Dec;27(12):2799-805.

ReferenceCitation: Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA. 2001 Aug 22-29;286(8):944-53. Review.

ReferenceCitation: Heys SD, Walker LG, Smith I, Eremin O. Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials. Ann Surg. 1999 Apr;229(4):467-77.

ReferenceCitation: Bower RH, Cerra FB, Bershadsky B, Licari JJ, Hoyt DB, Jensen GL, Van Buren CT, Rothkopf MM, Daly JM, Adelsberg BR. Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit Care Med. 1995 Mar;23(3):436-49.

ReferenceCitation: Tepaske R, Velthuis H, Oudemans-van Straaten HM, Heisterkamp SH, van Deventer SJ, Ince C, Eÿsman L, Kesecioglu J. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. Lancet. 2001 Sep 1;358(9283):696-701.

ReferenceCitation: Melchior JC. [How to assess preoperative nutritional status?]. Ann Fr Anesth Reanim. 1995;14 Suppl 2:19-26. French.

ReferenceCitation: Johnson JA, Cogbill TH, Strutt PJ, Gundersen AL. Wound complications after infrainguinal bypass. Classification, predisposing factors, and management. Arch Surg. 1988 Jul;123(7):859-62.

location_facility: CHU de NICE, Department of Vascular Surgery

intervention_type: Dietary Supplement


title: Phase 2 Study Evaluating the Efficacy of Epoetin Beta (Neocormon®) For Fatigue and Quality of Life of Patients Receiving Palliative Care for a Solid Malignant Tumor

summary:
RATIONALE: Epoetin beta may cause the body to make more red blood cells and may help relieve fatigue in patients with malignant solid tumors receiving palliative care.

PURPOSE: This phase II trial is studying how well epoetin beta works in treating fatigue and anemia in patients receiving palliative care for malignant solid tumors.

primary_purpose: Supportive Care

location_facility: Centre Hospital Regional Universitaire de Limoges


title: Phase 2 Study Evaluating the Feasibility and the Reproducibility of Concentrated Radiotherapy and Focalized Electrontherapy During Surgery for the Treatment of Older Patients With Breast Cancer

summary:
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving intraoperative radiation therapy may reduce the amount of normal tissue that needs to be removed.

PURPOSE: This phase II trial is studying how well giving radiation therapy during surgery works in treating older women with stage I breast cancer.

intervention_type: Radiation


title: Intrapulmonary Percussive Ventilation and Nasal Continuous Positive Airway Pressure Ventilation in Transient Respiratory Distress of the Newborn: A Randomized Controlled Trial

acronym: HFPV

summary: During caesarean section, transient respiratory distress which occurs frequently (3%) with possible complications are at present managed by non invasive nasal continuous positive airway pressure ventilation (nCPAP) associated with oxygen therapy. Intrapulmonary Percussive Ventilation (IPV) is a non-invasive ventilatory mode used in some intensive care units to treat some respiratory distress syndrome of the newborn with a good tolerance, but without evaluation in prospective studies

ReferenceCitation: Dumas De La Roque E, Bertrand C, Tandonnet O, Rebola M, Roquand E, Renesme L, Elleau C. Nasal high frequency percussive ventilation versus nasal continuous positive airway pressure in transient tachypnea of the newborn: a pilot randomized controlled trial (NCT00556738). Pediatr Pulmonol. 2011 Mar;46(3):218-23. doi: 10.1002/ppul.21354. Epub 2010 Oct 20.

family: Dumas De La Roque

full_name: Eric Dumas De La Roque

given: Eric

family: Bertrand

full_name: Clotilde Bertrand

given: Clotilde

family: Tandonnet

full_name: Olivier Tandonnet

given: Olivier

family: Rebola

full_name: Muriel Rebola

given: Muriel

family: Roquand

full_name: Emilie Roquand

given: Emilie

family: Renesme

full_name: Laurent Renesme

given: Laurent

family: Elleau

full_name: Christophe Elleau

given: Christophe

journal_name: Pediatric Pulmonology

publisher: Wiley

publisher_dissemination: Wiley

publisher_group: Wiley

publisher_normalized: Wiley

title: Nasal high frequency percussive ventilation versus nasal continuous positive airway pressure in transient tachypnea of the newborn: A pilot randomized controlled trial (NCT00556738)

location_facility: Néonatalogie - Maternité - Hôpital Pellegrin


title: Phase 1-2 Study of the Association of Gemzar ® - Cisplatin-concurrent Radiotherapy in Patients With Non-metastatic Tumors of the Bladder

acronym: GEMCIRAV

summary:
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of gemcitabine when given together with cisplatin and radiation therapy and to see how well they work in treating patients with stage II or stage III bladder cancer.


title: Phase II Study Evaluating the Efficacy and Safety of cétuximab Associated With the Protocol FOLFIRINOX (LV5FU Simplified Combined With Irinotecan and Oxaliplatin) in the First Line Treatment in Patients With Metastatic Colorectal Cancer Expressing EGFR or Not

summary:
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cetuximab together with combination chemotherapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving cetuximab together with combination chemotherapy works as first-line therapy in treating patients with metastatic colorectal cancer.


title: Interest of Biofer ® Compound Used in Blédilait Follow on Milk and Growing Milk on Iron Status Evolution in Infant With Latent Iron Deficiency

summary: The primary purpose of the study is to demonstrate the superiority of Bledilait milk (Biofer® 2mg/100kcal) in comparison with ferrous sulphate supplemented milk (2 mg/100 kcal) in infants (6 to 12 months) with latent iron deficiency by measuring serum ferritin value after 2 months of consumption of studied milks.

status: Suspended

lead_sponsor: Bledina


title: Effect of Continuous Positive Airway Pressure on Short Term Inhospital Prognosis for Acute Pulmonary Edema

acronym: CPAP

summary: The investigators hypothesise that CPAP + pharmaceutical treatment, compared to pharmaceutical treatment alone, improves the respiratory and hemodynamic status of the patients before H2 after the inclusion time and decreases the rate of death and tracheal intubation during the first 48 hours.

ReferenceCitation: Ducros L, Logeart D, Vicaut E, Henry P, Plaisance P, Collet JP, Broche C, Gueye P, Vergne M, Goetgheber D, Pennec PY, Belpomme V, Tartière JM, Lagarde S, Placente M, Fievet ML, Montalescot G, Payen D; CPAP collaborative study group. CPAP for acute cardiogenic pulmonary oedema from out-of-hospital to cardiac intensive care unit: a randomised multicentre study. Intensive Care Med. 2011 Sep;37(9):1501-9. doi: 10.1007/s00134-011-2311-4. Epub 2011 Jul 30.

family: Ducros

full_name: Laurent Ducros

name: on behalf of the CPAP collaborative study group

family: Logeart

full_name: Damien Logeart

given: Damien

family: Vicaut

full_name: Eric Vicaut

family: Henry

full_name: Patrick Henry

given: Patrick

family: Plaisance

full_name: Patrick Plaisance

family: Collet

full_name: Jean-Philippe Collet

given: Jean-Philippe

family: Broche

full_name: Claire Broche

given: Claire

family: Gueye

full_name: Papa Gueye

given: Papa

family: Vergne

full_name: Muriel Vergne

family: Goetgheber

full_name: David Goetgheber

given: David

family: Pennec

full_name: Pierre-Yves Pennec

given: Pierre-Yves

family: Belpomme

full_name: Vanessa Belpomme

given: Vanessa

family: Tartière

full_name: Jean-Michel Tartière

given: Jean-Michel

family: Lagarde

full_name: Sophie Lagarde

given: Sophie

family: Placente

full_name: Marius Placente

given: Marius

family: Fievet

full_name: Marie-Laurence Fievet

given: Marie-Laurence

family: Montalescot

full_name: Gilles Montalescot

given: Gilles

family: Payen

full_name: Didier Payen

given: Didier

journal_name: Intensive Care Medicine


title: Arthroplasty Versus Fusion in Anterior Cervical Surgery: Prospective Study of the Impact on the Adjacent Level

acronym: PROCERV

summary: The aim of the study is to evaluate the impact of the cervical disk surgery on the deterioration of the adjacent levels. The investigators compare the radiological deterioration of adjacent levels, at 3 years, in both situation of fusion and arthroplasty. 220 patients are enrolled and randomized to receive fusion or prosthesis. Radiological and clinical follow-up is organized for a period of 3 years.

ReferenceCitation: Dmitriev AE, Cunningham BW, Hu N, Sell G, Vigna F, McAfee PC. Adjacent level intradiscal pressure and segmental kinematics following a cervical total disc arthroplasty: an in vitro human cadaveric model. Spine (Phila Pa 1976). 2005 May 15;30(10):1165-72.

ReferenceCitation: Eck JC, Humphreys SC, Lim TH, Jeong ST, Kim JG, Hodges SD, An HS. Biomechanical study on the effect of cervical spine fusion on adjacent-level intradiscal pressure and segmental motion. Spine (Phila Pa 1976). 2002 Nov 15;27(22):2431-4.

ReferenceCitation: Hilibrand AS, Robbins M. Adjacent segment degeneration and adjacent segment disease: the consequences of spinal fusion? Spine J. 2004 Nov-Dec;4(6 Suppl):190S-194S. Review.

ReferenceCitation: Goffin J, Geusens E, Vantomme N, Quintens E, Waerzeggers Y, Depreitere B, Van Calenbergh F, van Loon J. Long-term follow-up after interbody fusion of the cervical spine. J Spinal Disord Tech. 2004 Apr;17(2):79-85.

ReferenceCitation: Link HD, McAfee PC, Pimenta L. Choosing a cervical disc replacement. Spine J. 2004 Nov-Dec;4(6 Suppl):294S-302S. Review.

ReferenceCitation: Albert TJ, Eichenbaum MD. Goals of cervical disc replacement. Spine J. 2004 Nov-Dec;4(6 Suppl):292S-293S. Review.

ReferenceCitation: McAfee PC. The indications for lumbar and cervical disc replacement. Spine J. 2004 Nov-Dec;4(6 Suppl):177S-181S. Review.

ReferenceCitation: Fager CA. Cervical arthroplasty. J Neurosurg Spine. 2005 Mar;2(3):394-5; author reply 395.

ReferenceCitation: Phillips FM, Garfin SR. Cervical disc replacement. Spine (Phila Pa 1976). 2005 Sep 1;30(17 Suppl):S27-33. Review.

ReferenceCitation: Pracyk JB, Traynelis VC. Treatment of the painful motion segment: cervical arthroplasty. Spine (Phila Pa 1976). 2005 Aug 15;30(16 Suppl):S23-32. Review.

ReferenceCitation: Hacker RJ. Cervical disc arthroplasty: a controlled randomized prospective study with intermediate follow-up results. Invited submission from the joint section meeting on disorders of the spine and peripheral nerves, March 2005. J Neurosurg Spine. 2005 Dec;3(6):424-8. Erratum in: J Neurosurg Spine. 2006 Feb;4(2):189.

ReferenceCitation: Robertson JT, Papadopoulos SM, Traynelis VC. Assessment of adjacent-segment disease in patients treated with cervical fusion or arthroplasty: a prospective 2-year study. J Neurosurg Spine. 2005 Dec;3(6):417-23.

ReferenceCitation: Singh M, Gopinath R. Topical analgesia for chest tube removal in cardiac patients. J Cardiothorac Vasc Anesth. 2005 Dec;19(6):719-22.

ReferenceCitation: Chi JH, Ames CP, Tay B. General considerations for cervical arthroplasty with technique for ProDisc-C. Neurosurg Clin N Am. 2005 Oct;16(4):609-19, vi. Review.

ReferenceCitation: Bertagnoli R, Yue JJ, Pfeiffer F, Fenk-Mayer A, Lawrence JP, Kershaw T, Nanieva R. Early results after ProDisc-C cervical disc replacement. J Neurosurg Spine. 2005 Apr;2(4):403-10.

ReferenceCitation: Puttlitz CM, Rousseau MA, Xu Z, Hu S, Tay BK, Lotz JC. Intervertebral disc replacement maintains cervical spine kinetics. Spine (Phila Pa 1976). 2004 Dec 15;29(24):2809-14.

ReferenceCitation: Puttlitz CM, DiAngelo DJ. Cervical spine arthroplasty biomechanics. Neurosurg Clin N Am. 2005 Oct;16(4):589-94, v. Review.

ReferenceCitation: Pickett GE, Rouleau JP, Duggal N. Kinematic analysis of the cervical spine following implantation of an artificial cervical disc. Spine (Phila Pa 1976). 2005 Sep 1;30(17):1949-54.

ReferenceCitation: Parkinson JF, Sekhon LH. Cervical arthroplasty complicated by delayed spontaneous fusion. Case report. J Neurosurg Spine. 2005 Mar;2(3):377-80.

ReferenceCitation: Murray BE, Lopardo HA, Rubeglio EA, Frosolono M, Singh KV. Intrahospital spread of a single gentamicin-resistant, beta-lactamase-producing strain of Enterococcus faecalis in Argentina. Antimicrob Agents Chemother. 1992 Jan;36(1):230-2.

ReferenceCitation: Bertagnoli R, Duggal N, Pickett GE, Wigfield CC, Gill SS, Karg A, Voigt S. Cervical total disc replacement, part two: clinical results. Orthop Clin North Am. 2005 Jul;36(3):355-62.

ReferenceCitation: Pickett GE, Sekhon LH, Sears WR, Duggal N. Complications with cervical arthroplasty. J Neurosurg Spine. 2006 Feb;4(2):98-105.